Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. OMERACT Definitions for Ultrasonographic Pathologies and Elementary Lesions of Rheumatic Disorders 15 Years On

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: The aim of the study was to establish the antiinflammatory equipotency between prednisolone and deflazacort.

METHODS: Thirty patients with newly diagnosed polymyalgia rheumatica (PMR) were treated double blind with either prednisolone or deflazacort in a 12-month study. The initial daily dose was 20 mg prednisolone or 24 mg deflazacort.

RESULTS: The clinical control of muscle pain was significantly inferior in the deflazacort group from 6 weeks to 3 months. Otherwise there was no difference in the clinical and biochemical variables. The ratio between antiinflammatory equipotent doses of deflazacort and prednisolone (mg:mg) stabilized at about 1.55 for the daily doses and about 1.40 for the cumulative doses.

CONCLUSION: In PMR the antiinflammatory equipotency (mg to mg) between deflazacort and prednisolone was close to 1.40 (7:5 mg). Twenty mg prednisolone/day was fully sufficient to suppress symptoms in 94% of the patients.

OriginalsprogEngelsk
TidsskriftJournal of Rheumatology
Vol/bind22
Udgave nummer9
Sider (fra-til)1660-2
Antal sider3
ISSN0315-162X
StatusUdgivet - sep. 1995

ID: 45105101